

## CONTENTS

---

### INDEX

#### CONTENT OVERVIEW

<b>S. No.</b>	<b>Content</b>	<b>Page No.</b>
1	Abstract	1
2	Chapter 1: Introduction and Review of Literature	4
3	Chapter 2: Aims & Objectives	92
4	Chapter 3: Materials & Methods	97
5	Chapter 4: Cloning, Expression and Purification of Recombinant full-length huntingtin proteins with SA or SD mutations	119
6	Chapter 5: To Study the impact of phosphorylation status of Ser13 and Ser16 of normal and mutant huntingtin on PRC2 activity using cell-free and cell-based models	135
7	Chapter 6: Deciphering the global impact of phosphorylation status of Ser13 and Ser16 on mutant huntingtin (mHTT) toxicity	152
8	Chapter 7: Identification of differentially expressed proteins associated with mHTT expression using quantitative proteomics approach	192
9	Chapter 8: Studying the peripheral effects of mutant huntingtin (mHTT) expression in cell line models of HD	215
10	Chapter 9: Summary and Conclusion	231
11	List of Publications	240
12	Reprints of Published Articles	244

**DETAILED CONTENT**

<b>Content</b>	<b>Page No.</b>
<b>ABSTRACT</b>	<b>1-3</b>
<b>1. INTRODUCTION &amp; REVIEW OF LITERATURE (Chapter 1)</b>	<b>4-91</b>
1.1 Neurodegenerative Diseases	<b>5</b>
1.1.1 Alzheimer's disease	<b>7</b>
1.1.2 Parkinson's disease	<b>8</b>
1.1.3 Amyotrophic lateral sclerosis	<b>8</b>
1.1.4 Huntington's disease	<b>9</b>
1.2 Huntington's disease	<b>9</b>
1.2.1 Historical perspective	<b>9</b>
1.2.2 Epidemiology	<b>10</b>
1.2.3 The Genetic Basis of Huntington's Disease	<b>11</b>
1.2.4 Clinical features of Huntington's disease	<b>13</b>
1.2.5 Pathophysiology of Huntington's Disease	<b>15</b>
1.2.6 Peripheral Pathology in Huntington's Disease	<b>16</b>
1.2.7 The diagnosis of Huntington's Disease	<b>18</b>
1.3 The Huntingtin (HTT) protein	<b>18</b>
1.3.1 Wild-type Huntingtin structure	<b>18</b>
1.3.2 Wild-type Huntingtin function	<b>20</b>
1.3.3 Mutant Huntingtin protein (mHTT)	<b>21</b>
1.3.4 N-terminal huntingtin	<b>23</b>

## CONTENTS

---

1.4 Misfolding and Aggregation of mHTT in Huntington's Disease	24
1.5 Role of PRC2 Complex in HD pathology	26
1.6 Consequences of expansion of polyQ length in mutant huntingtin protein	28
1.6.1 Cell-autonomous pathogenesis	28
1.6.2 Non-cell-autonomous pathogenesis	35
1.6.3 Transcriptional dysregulation in HD	36
1.7 Huntington's Disease Therapeutics	37
1.7.1 Current therapeutics for HD	38
1.7.2 Experimental therapeutics for HD	38
1.7.3 Post-transcriptional gene silencing	39
1.7.4 HTT-lowering in HD	39
1.7.5 Allele-selective HTT-lowering	40
1.7.6 Protein Clearance Approaches to Lowering Mutant Huntingtin	40
1.8 Huntingtin Post-translational Modifications	41
1.8.1 Phosphorylation of HTT	41
1.8.2 Ser13/Ser16 Phosphorylation	42
1.9 Kinase and Phosphatase Inhibitors as Huntington's Disease Therapeutics	43
1.10 References	44
<b>2. AIMS &amp; OBJECTIVES (Chapter 2)</b>	<b>92-96</b>
2.1 Rationale and Hypothesis	93
2.2 Proposed Objectives	94

## CONTENTS

<b>3. MATERIALS &amp; METHODS (Chapter 3)</b>	<b>97-118</b>
3.1 Materials	<b>98</b>
3.1.1 Cell lines	<b>98</b>
3.1.2 Chemicals and reagents	<b>100</b>
3.1.3 Constructs	<b>100</b>
3.2 Methodology	<b>102</b>
3.2.1 Cloning, Expression and Purification of Recombinant full-length huntingtin proteins with SA or SD mutation	<b>102</b>
3.2.2 Expression and purification of the Polycomb Repressive Complex 2 (PRC2) using <i>Sf9</i> insect cell Baculovirus system and affinity chromatography	<b>104</b>
3.2.3 The reconstituted <i>in-vitro</i> PRC2 activity assay	<b>105</b>
3.2.4 Analyzing effect of specific kinase and phosphatase inhibitors on <i>in-vivo</i> PRC2 activity in cell line models of HD	<b>106</b>
3.2.5 Fluorescence Microscopy	<b>107</b>
3.2.6 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and western blotting	<b>107</b>
3.2.7 Real time PCR (RT-qPCR)	<b>108</b>
3.2.8 Mitochondrial ROS determination	<b>108</b>
3.2.9 ATP levels	<b>109</b>
3.2.10 Cell viability assay	<b>109</b>
3.2.11 Identification of differentially expressed proteins associated with mHTT expression using label-free quantitative proteomics approach	<b>109</b>

## CONTENTS

3.2.12 Generation and characterization of Lymphoblastoid Cell lines (LCLs) from Control and Huntington's Disease patients	<b>112</b>
3.2.13 Treatment of Lymphoblastoid Cell Lines (LCLs) with Kinetin, BMS 345541, and Bay 11-7082	<b>115</b>
3.2.14 Investigation of the Effects of HD150Q Cell Secretome on Immune Cells Expressing Normal Huntingtin	<b>116</b>
3.2.15 Statistical Analysis	<b>117</b>
3.3 References	<b>118</b>
<b>RESULTS AND DISCUSSION</b>	
<b>4. To Study the impact of phosphorylation status of Ser13 and Ser16 of normal and mutant huntingtin on PRC2 activity using cell-free and cell-based models (Chapter 4)</b>	<b>119-134</b>
4.1 Characterization of Full-Length Huntingtin Baculovirus Constructs with Ser13 and Ser16 Substituted to Alanine or Aspartate	<b>120</b>
4.2 Expression of Huntingtin Proteins with SA or SD Mutations in <i>Sf9</i> Insect Cells and its Purification: Yields and Protein Analysis	<b>127</b>
4.3 Discussion	<b>132</b>
4.4 References	<b>133</b>
<b>5. To Study the impact of phosphorylation status of Ser13 and Ser16 of normal and mutant huntingtin on PRC2 activity using cell-free and cell-based models (Chapter 5)</b>	<b>135-151</b>
5.1 Expression and Purification of Polycomb Repressive Complex 2 (PRC2) using the <i>Sf9</i> Insect Cell Baculovirus System and Affinity Chromatography	<b>138</b>
5.2 Impact of Huntingtin Phosphomimetic Mutations on PRC2-Mediated H3K27 Trimethylation Activity in a PolyQ-Dependent Manner	<b>141</b>

## CONTENTS

5.3 Kinetin, BMS 345541, and Bay 11-7082 Increases Phosphorylation of Ser13/Ser16 in Mouse Striatal Cells Expressing Mutant Huntingtin	143
5.4 Kinetin, BMS 345541, and Bay 11-7082 reduces PRC2-Mediated Histone H3 Lysine 27 Trimethylation in Mouse Striatal Cell Lines	145
5.5 Discussion	146
5.6 References	147
<b>6. Deciphering the global impact of phosphorylation status of Ser13 and Ser16 on mutant huntingtin (mHTT) toxicity (Chapter 6)</b>	<b>152-191</b>
6.1 Kinetin, BMS 345541, and Bay 11-7082 Increase Phosphorylation of Ser13/Ser16 in HD150Q Cells Expressing Mutant Huntingtin	154
6.2 Kinetin, BMS 345541, and Bay 11-7082 Prevent and/or Reduce mHTT Aggregates	157
6.3 Kinetin, BMS 345541, and Bay 11-7082 Rescues mHTT-Induced Mitochondrial Dysfunction	166
6.4 Kinetin, BMS 345541, and Bay 11-7082 Play a Vital Role in the Regulation of ER Stress Induced by mHTT	173
6.5 Kinetin, BMS 345541, and Bay 11-7082 Improve Cell Viability	179
6.6 Discussion	183
6.7 References	186
<b>7. Identification of differentially expressed proteins associated with mHTT expression using quantitative proteomics approach (Chapter 7)</b>	<b>192-214</b>
7.1 Label-Free Quantitation and Comparative Analysis	193
7.2 Comparative Analysis of Proteomic Alterations in HD150Q Cells treated with Pon A alone and Post-Treatment with Kinetin, BMS 345541, and Bay 11-7082	196

## CONTENTS

7.2.1 Downregulated Pathways in HD Condition vs. Upregulated Pathways Post-Treatment	<b>196</b>
7.2.2 Upregulated Pathways in HD Condition vs. Downregulated Pathways Post-Treatment	<b>198</b>
7.3 Comparative Analysis of Biological Processes in Pon A treated HD150Q Cells and Post-Treatment with Kinetin, BMS 345541, and Bay 11-7082	<b>200</b>
7.3.1 Downregulated Biological Processes in HD Condition vs. Upregulated Biological Processes Post-Treatment	<b>201</b>
7.3.2 Upregulated Biological Processes in HD Condition vs. Downregulated Biological Processes Post-Treatment	<b>202</b>
7.4 Comparative Analysis of Cellular Components in Pon A treated HD150Q Cells and Post-Treatment with Kinetin, BMS 345541, and Bay 11-7082	<b>204</b>
7.4.1 Downregulated Cellular Components in HD Condition vs. Upregulated Cellular Components Post-Treatment	<b>206</b>
7.4.2 Upregulated Cellular Components in HD Condition vs. Downregulated Cellular Components Post-Treatment	<b>206</b>
7.5 Discussion	<b>208</b>
7.6 References	<b>210</b>
<b>8. Studying the peripheral effects of mutant huntingtin (mHTT) expression in cell line models of HD (Chapter 8)</b>	<b>215-230</b>
8.1 Establishment and Characterization of Lymphoblastoid Cell Lines (LCLs) from Healthy Controls and Huntington's Disease Patients	<b>216</b>
8.1.1 Epstein Barr Virus (EBV) Production	<b>216</b>
8.1.2 Generation of Lymphoblastoid Cell Lines (LCLs)	<b>218</b>
8.1.3 Characterization of Lymphoblastoid Cell Lines (LCLs)	<b>219</b>

## CONTENTS

8.2 Effect of Kinetin, BMS 345541, and Bay 11-7082 on Inflammatory Marker Gene Expression in HD LCL Cells	221
8.3 Impact of HD150Q Cell Secretome on Immune Cells Expressing Normal Huntingtin	223
8.3.1 Gene Expression Changes in PBMCs and THP-1 Cells	223
8.3.2 ATP Levels in <i>STHdh</i> <sup>Q7/Q7</sup> Cells	224
8.3.3 Effect of Ponasterone A and Kinetin-treated HD150Q Secretome on ATP Levels	224
8.4 Discussion	225
8.5 References	227
<b>9. SUMMARY &amp; CONCLUSION (Chapter 9)</b>	<b>231-239</b>
9.1 Summary	232
9.1.1 Cloning, Expression and Purification of Recombinant full-length huntingtin proteins with SA or SD mutations	232
9.1.2 To Study the impact of phosphorylation status of Ser13 and Ser16 of normal and mutant huntingtin on PRC2 activity using cell-free and cell-based models	232
9.1.3 Deciphering the global impact of phosphorylation status of Ser13 and Ser16 on mutant huntingtin (mHTT) toxicity	233
9.1.4 Identification of differentially expressed proteins associated with mHTT expression using quantitative proteomics approach	234
9.1.5 Studying the peripheral effects of mutant huntingtin (mHTT) expression in cell line models of HD	235
9.2 Conclusion	236
9.3 Limitations of the study	237

## CONTENTS

---

9.4 Future Perspectives	238
<b>10. LIST OF PUBLICATIONS</b>	<b>240-243</b>
10.1 Publications from Ph.D. Thesis work	241
10.2 Publications from other associated Projects during Ph.D. tenure	241
<b>11. REPRINT OF PUBLISHED ARTICLES</b>	<b>244</b>